Navigation Links
Study shows Hodgkin lymphoma survivors lack post-treatment screening for other cancers
Date:6/10/2010

A population-based study of 2,071 Hodgkin lymphoma (HL) survivors over 15 years has discovered that while many survivors had multiple X-rays and CT scans years after treatment was finished, they often did not receive recommended cancer screening tests.

The study, available online ahead of print publication in the July issue of the American Cancer Society journal Cancer (www.interscience.wiley.com DOI 10.1002/cncr.25053), followed the survivors for up to 15 years after their HL diagnosis by evaluating physician visits, imaging studies, and the use of routine and HL-specific cancer screening tests.

Survivors had CT scans at a rate three times greater than in the general population, even 10 to 15 years after their original diagnosis. "It is not clear why the CT scans were ordered, but they certainly did not appear to be an efficient way to detect relapse, particularly this long after treatment was finished," says principal investigator David Hodgson, a radiation oncologist at the Princess Margaret Hospital Cancer Program, University Health Network, and investigator at the Institute of Clinical Evaluative Sciences.

Most HL patients never experience a relapse. For those who do, they usually know something is wrong before their doctor does. It is uncommon to detect relapse with CT alone in a patient who is feeling well.

"For these patients, the telephone, not the CT scanner, is the most important technology," says Dr. Hodgson. "Oncologists need to advise their patients what symptoms should prompt them to seek medical attention and physicians have to be able to evaluate them in a timely way to decide if imaging is needed."

Despite frequent contact with both specialists and primary care providers, many survivors did not receive recommended cancer screening tests. Among those who met criteria for routine screening, 62.5% were not screened for colorectal cancer, 32.3%
'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.on.ca
416-946-2846
University Health Network
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Genome-wide study identifies factors that may affect vitamin D levels
2. Study finds poor compliance with cirrhosis surveillance recommendations
3. Study finds beta blockers alone more effective for first variceal bleeding
4. Sleep colors your view of the world: Study suggests sleep may restore color perception
5. Video study finds risky food-safety behavior more common than thought
6. Few health reform options would have covered more people at lower cost than new law, study finds
7. Genetic markers could predict prostate cancer in younger men, U-M study finds
8. Study: Mining is a major driver of sub-Saharan Africas TB epidemic
9. U of M study: Monitoring cholesterol increases life expectancy
10. Study finds a seasonal variance in sleep-disordered breathing in young children
11. Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Don Allred Insurance, a leading provider of home, ... Carolina residents, is excited to announce the Grand Opening ... The new branch has been up and running since ... facets of the insurance selection process from quote comparison ... couldn’t be happier with the timing of this Grand ...
(Date:10/30/2014)... OR (PRWEB) October 30, 2014 Five ... firm Hodgkinson Street LLC announces new branding and ... Hodgkinson Street Mepham . After David Mepham’s promotion to ... their brand and website to include Mepham’s name and ... medical malpractice and mediation firm, the decision to implement ...
(Date:10/30/2014)... N.C. (PRWEB) October 30, 2014 Paramount ... health care, is increasing efforts to help people save ... expenses continue to increase for prescription drugs in the ... valuable savings and resources to bridge the relationship between ... One of the biggest challenges people face today with ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... By Dennis Thompson ... -- The Ebola outbreak in Liberia -- one of three ... slowing, World Health Organization officials said Wednesday. Dr. Bruce ... in the number of burials in Liberia and no increase ... the global push to tame the epidemic may be making ...
Breaking Medicine News(10 mins):Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... the Stimulus Bil provide big boost for the conversion to electronic medical ... document scanning and document management systems. , ... Lakewood, CO (PRWEB) March ... to convert their paper records to digital files. Medical record scanning ...
... how precious it really is. 24k gold is a key ingredient in ... , ... York (PRWEB) March 6, 2009 -- While watching CNBC or other major news ... hear that it has kept a rather high value during this economic recession. ...
... continues to impose a huge burden on industrialized societies, ... absence. Annual costs related to back pain in the ... billion per year. , But a systematic review of ... February issue of The Spine Journal finds ...
... first, studies suggest , , THURSDAY, March 5 (HealthDay News) ... effective treatment is a short course of radiation therapy ... , Surgery is the standard treatment for rectal ... of cancer recurrence in the same area, according to ...
... (OTC Bulletin Board: POLGA ; OTC Bulletin Board: ... engineered materials, announced today it will release fourth quarter ... market on Wednesday, March 18, 2009. Company officials will ... at 10:00 a.m. EDT on Thursday, March 19, 2009. ...
... Dr. Steven St. Peter Named to Proteon Board of ... of the world,s largest life sciences-dedicated venture capital investors, ... a $38 million Series B equity financing of Proteon ... of MPM Capital, has been named to the Proteon ...
Cached Medicine News:Health News:Stimulus Package Boosts Medical Document Scanning 2Health News:Gold Not Only Valuable, It's a Healthy Skin Care Ingredient 2Health News:Clinical trials' review finds only exercise to prevent low-back problems 2Health News:Rectal Cancer Outcomes Best With Short-Course Radiation 2Health News:Rectal Cancer Outcomes Best With Short-Course Radiation 3Health News:Polymer Group, Inc. Announces Fourth Quarter and Year-End 2008 Earnings Conference Call 2Health News:MPM Capital Leads Investment in Proteon Therapeutics 2
(Date:10/30/2014)... -- Stryker Orthopaedics, the Official Joint Replacement Products of ... its debut year of the relationship at the Charles ... This marks the eleventh tournament stop along both ... has activated on-site with the "Stryker Mobility Zone" – ... importance of joint health.  The Stryker ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Electronic ... dramatically as a result of government initiatives and ... - healthcare providers have invested over the past ... heart of health IT, and U.S. clinicians use ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... United Kingdom , Oct. 30, 2014 ... (Nasdaq: CBRX ) and Maryland ... drug developers with improved efficiency during clinical development that ... Diego next week. This partnership ... technologies platform, which it launched earlier this month. The ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... International Partnership for Microbicides, issued the following statement ... and effectiveness study of BufferGel and PRO2000 (0.5 ... Microbicide Trials Network, a worldwide collaborative group funded ... released final results from its Phase II/IIb safety ...
... Only Approved Platelet Producer in Europe Represents New ... Feb. 6 Amgen (Nasdaq: AMGN ... has granted marketing authorisation for Nplate(R) (romiplostim) for ... thrombocytopenic purpura (ITP) patients who are refractory to ...
Cached Medicine Technology:New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 2New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 3New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8
Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
Medicine Products: